腹部克罗恩病的管理方法
Taylor Carter1, Van Hoang1, Muneera R Kapadia1
1Department of Surgery, University of North Carolina at Chapel Hill, Burnett Womack Building, Suite 4038, Campus Box 7081, Chapel Hill, NC 27599-7081, USA.
The Surgical clinics of North America
|November 15, 2025
概括
克罗恩氏病 (CD) 是一种慢性胃肠道疾病,需要管理. 虽然医疗治疗的目的是缓解,但由于疾病进展和并发症,许多患者最终需要手术.
科学领域:
- 胃肠病学 胃肠病学
- 炎症性肠道疾病研究研究
- 外科胃肠道外科手术
背景情况:
- 克罗恩氏病 (CD) 是一种慢性,复发性炎症状况,影响整个胃肠道.
- 患病率的增加影响了不同年龄段的人群,从青少年到老年人.
- 目前的医疗管理重点是实现无类固醇的临床和内镜缓解.
研究的目的:
- 审查手术干预在克罗恩病管理中的作用和变异性.
- 突出CD患者从医疗到外科治疗的进展.
- 强调手术干预对缓解症状和预防并发症的重要性.
主要方法:
- 对克罗恩病管理现有文献的综述.
- 分析治疗途径,包括药物和手术选择.
- 根据疾病表型和位置,检查影响外科手术方法的因素.
主要成果:
- 医疗治疗是最初的方法,目的是缓解.
- 很大一部分患者最终需要手术.
- 手术的结果和方法是根据个体疾病特征量身定制的.
结论:
- 手术仍然是管理晚期或耐火克罗恩病的关键组成部分.
- 根据疾病表型和位置定制手术干预对于最佳的患者结果至关重要.
- 手术管理旨在改善克罗恩病患者的生活质量并预防严重并发症.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Inflammatory Bowel Disease V: Surgical Management
430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
430
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420
Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
622
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470


